Skip to content
DraconiticResearch
Search Sources API
210,049 studies31 sourcesUpdated 17 min ago
Peer-reviewedCC BY-NC-ND 4.0npj Parkinson's Disease

fMRI during active GPi DBS uncovers target-specific networks

6 more authors
6 affiliations
  1. 1Division of Neurosurgery, Department of Surgery, University of Toronto
  2. 2GE HealthCare Technology & Innovation Center, Niskayuna
  3. 3Edmond J. Safra Program in Parkinson’s Disease and Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, UHN
  4. 4Department of Clinical Neurological Sciences, Western University
  5. 5University Health Network, University of Toronto
  6. 6Krembil Brain Institute

Abstract

Improved understanding of target-specific changes in brain activity during deep-brain stimulation (DBS) for Parkinson’s disease (PD) may refine target selection. Here, we study the network effects of active DBS using functional magnetic resonance imaging (fMRI) during stimulation of the subthalamic nucleus (STN) and globus pallidus internus (GPi). About 36 PD patients (62.5 ± 8.1 years, 18 GPi-DBS, 39% female) underwent prospective fMRI during active DBS. DBS produced distributed cortical modulation associated with clinical improvement at the group level. Network modeling revealed symptom-specific coupling, with somatomotor network modulation significantly associated with gait improvement (ΔR² = 0.40, p FDR = 0.03) and showing a weaker association with bradykinesia improvement (ΔR² = 0.32, p FDR = 0.06). Unexpectedly, somatomotor network modulation showed a nominal association with variability in verbal fluency outcomes (ΔR² = 0.28, p FDR = 0.08), whereas language and cognitive networks demonstrated minimal explanatory value. A comparable relationship between network modulation and verbal fluency was not observed in STN-DBS. These findings demonstrate that DBS therapeutic effects are best understood as modulation of distributed functional networks rather than focal regions, with target-dependent network coupling potentially underlying differential cognitive outcomes.

Related

  1. A Drug-Specific, Half-Life-Adjusted Framework for Classifying CNS-Active Systemic Therapy Exposure During and After Radiotherapy
    L. Pari Mitre, B. Drapkin, M. Dohopolski
    medRxivPreprintAll rights reservedFull textEpidemiology & public healthmedRxiv
  2. Multisystem Outcomes of GLP-1 Receptor Agonists Versus Active Comparators in Type 2 Diabetes: A Multicenter Target Trial Emulation
    Rohit Vashisht, Sanket S. Dhruva, Ayan Patel +8
    Journal of Diabetes Science and TechnologyPeer-reviewedLicence not statedFull textEndocrinology & metabolismPMC
  3. Target Specific Conformational Flexibility and Electrostatic Complementarity Modulate LTNF10 Peptide Binding to Phospholipase A2 Variants from Snake Venoms
    A. Gupta, M. M. Sena, B. Singh
    bioRxivPreprintAll rights reservedFull textPharmacology & toxicologybioRxiv
  4. A UCP1-IRES-Cre knock-in mouse enables specific brown adipocyte targeting without CNS off-target expression
    Joshua Meyer, Jaclyn Williams, Jennifer Bailey +3
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textPhysiologyCrossref
  5. From Active Compound to Target Epithelium: Local Delivery, Preclinical Model Validity, and Clinical Endpoint Interpretation in Topical Therapy for HPV-Associated Lower Genital Tract Disease—A Narrative Review
    Sandra Teodora Gavril, Răzvan Popovici, Iustina Petra Solomon Condriuc +5
    Journal of clinical medicinePeer-reviewedCC BYFull textEpidemiology & public healthEurope PMCCrossref
BibTeX
@article{santyr2026fmri,
  title = {{fMRI during active GPi DBS uncovers target-specific networks}},
  author = {Brendan Santyr and Clement Chow and Jürgen Germann and Alexandre Boutet and Afis Ajala and Jianwei Qiu and Arron Loh and Ibrahim Alhashyan and Mohamad Abbass and Gavin Elias and Can Sarica and Artur Vetkas and Andrew Yang and Desmond Yeo and Suneil Kalia and Melanie Cohn and Alfonso Fasano and Andres M. Lozano},
  journal = {npj Parkinson's Disease},
  year = {2026},
  month = jul,
  doi = {10.1038/s41531-026-01476-8},
  url = {https://doi.org/10.1038/s41531-026-01476-8},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - fMRI during active GPi DBS uncovers target-specific networks
AU  - Brendan Santyr
AU  - Clement Chow
AU  - Jürgen Germann
AU  - Alexandre Boutet
AU  - Afis Ajala
AU  - Jianwei Qiu
AU  - Arron Loh
AU  - Ibrahim Alhashyan
AU  - Mohamad Abbass
AU  - Gavin Elias
AU  - Can Sarica
AU  - Artur Vetkas
AU  - Andrew Yang
AU  - Desmond Yeo
AU  - Suneil Kalia
AU  - Melanie Cohn
AU  - Alfonso Fasano
AU  - Andres M. Lozano
PY  - 2026
DA  - 2026/07/01
JO  - npj Parkinson's Disease
DO  - 10.1038/s41531-026-01476-8
UR  - https://doi.org/10.1038/s41531-026-01476-8
AB  - Improved understanding of target-specific changes in brain activity during deep-brain stimulation (DBS) for Parkinson’s disease (PD) may refine target selection. Here, we study the network effects of active DBS using functional magnetic resonance imaging (fMRI) during stimulation of the subthalamic nucleus (STN) and globus pallidus internus (GPi). About 36 PD patients (62.5 ± 8.1 years, 18 GPi-DBS, 39% female) underwent prospective fMRI during active DBS. DBS produced distributed cortical modulation associated with clinical improvement at the group level. Network modeling revealed symptom-specific coupling, with somatomotor network modulation significantly associated with gait improvement (ΔR² = 0.40, p FDR = 0.03) and showing a weaker association with bradykinesia improvement (ΔR² = 0.32, p FDR = 0.06). Unexpectedly, somatomotor network modulation showed a nominal association with variability in verbal fluency outcomes (ΔR² = 0.28, p FDR = 0.08), whereas language and cognitive networks demonstrated minimal explanatory value. A comparable relationship between network modulation and verbal fluency was not observed in STN-DBS. These findings demonstrate that DBS therapeutic effects are best understood as modulation of distributed functional networks rather than focal regions, with target-dependent network coupling potentially underlying differential cognitive outcomes.
SN  - 2373-8057
ER  -